Cargando…
Long-term utilization and benefit of luspatercept in transfusion-dependent, erythropoiesis-stimulating agent-refractory or -intolerant patients with lower-risk myelodysplastic syndromes with ring sideroblasts
| Autores principales: | , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10624606/ https://www.ncbi.nlm.nih.gov/pubmed/37752285 http://dx.doi.org/10.1038/s41375-023-02031-7 |
| _version_ | 1785130950684835840 |
|---|---|
| author | Platzbecker, Uwe Santini, Valeria Komrokji, Rami S. Zeidan, Amer M. Garcia-Manero, Guillermo Buckstein, Rena Miteva, Dimana Keeperman, Karen Holot, Natalia Nadal, Jose Alberto Lai, Yinzhi Vodala, Sadanand Rosettani, Barbara Giuseppi, Ana Carolina Yucel, Aylin Fenaux, Pierre |
| author_facet | Platzbecker, Uwe Santini, Valeria Komrokji, Rami S. Zeidan, Amer M. Garcia-Manero, Guillermo Buckstein, Rena Miteva, Dimana Keeperman, Karen Holot, Natalia Nadal, Jose Alberto Lai, Yinzhi Vodala, Sadanand Rosettani, Barbara Giuseppi, Ana Carolina Yucel, Aylin Fenaux, Pierre |
| author_sort | Platzbecker, Uwe |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10624606 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Nature Publishing Group UK |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-106246062023-11-05 Long-term utilization and benefit of luspatercept in transfusion-dependent, erythropoiesis-stimulating agent-refractory or -intolerant patients with lower-risk myelodysplastic syndromes with ring sideroblasts Platzbecker, Uwe Santini, Valeria Komrokji, Rami S. Zeidan, Amer M. Garcia-Manero, Guillermo Buckstein, Rena Miteva, Dimana Keeperman, Karen Holot, Natalia Nadal, Jose Alberto Lai, Yinzhi Vodala, Sadanand Rosettani, Barbara Giuseppi, Ana Carolina Yucel, Aylin Fenaux, Pierre Leukemia Letter Nature Publishing Group UK 2023-09-26 2023 /pmc/articles/PMC10624606/ /pubmed/37752285 http://dx.doi.org/10.1038/s41375-023-02031-7 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
| spellingShingle | Letter Platzbecker, Uwe Santini, Valeria Komrokji, Rami S. Zeidan, Amer M. Garcia-Manero, Guillermo Buckstein, Rena Miteva, Dimana Keeperman, Karen Holot, Natalia Nadal, Jose Alberto Lai, Yinzhi Vodala, Sadanand Rosettani, Barbara Giuseppi, Ana Carolina Yucel, Aylin Fenaux, Pierre Long-term utilization and benefit of luspatercept in transfusion-dependent, erythropoiesis-stimulating agent-refractory or -intolerant patients with lower-risk myelodysplastic syndromes with ring sideroblasts |
| title | Long-term utilization and benefit of luspatercept in transfusion-dependent, erythropoiesis-stimulating agent-refractory or -intolerant patients with lower-risk myelodysplastic syndromes with ring sideroblasts |
| title_full | Long-term utilization and benefit of luspatercept in transfusion-dependent, erythropoiesis-stimulating agent-refractory or -intolerant patients with lower-risk myelodysplastic syndromes with ring sideroblasts |
| title_fullStr | Long-term utilization and benefit of luspatercept in transfusion-dependent, erythropoiesis-stimulating agent-refractory or -intolerant patients with lower-risk myelodysplastic syndromes with ring sideroblasts |
| title_full_unstemmed | Long-term utilization and benefit of luspatercept in transfusion-dependent, erythropoiesis-stimulating agent-refractory or -intolerant patients with lower-risk myelodysplastic syndromes with ring sideroblasts |
| title_short | Long-term utilization and benefit of luspatercept in transfusion-dependent, erythropoiesis-stimulating agent-refractory or -intolerant patients with lower-risk myelodysplastic syndromes with ring sideroblasts |
| title_sort | long-term utilization and benefit of luspatercept in transfusion-dependent, erythropoiesis-stimulating agent-refractory or -intolerant patients with lower-risk myelodysplastic syndromes with ring sideroblasts |
| topic | Letter |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10624606/ https://www.ncbi.nlm.nih.gov/pubmed/37752285 http://dx.doi.org/10.1038/s41375-023-02031-7 |
| work_keys_str_mv | AT platzbeckeruwe longtermutilizationandbenefitofluspaterceptintransfusiondependenterythropoiesisstimulatingagentrefractoryorintolerantpatientswithlowerriskmyelodysplasticsyndromeswithringsideroblasts AT santinivaleria longtermutilizationandbenefitofluspaterceptintransfusiondependenterythropoiesisstimulatingagentrefractoryorintolerantpatientswithlowerriskmyelodysplasticsyndromeswithringsideroblasts AT komrokjiramis longtermutilizationandbenefitofluspaterceptintransfusiondependenterythropoiesisstimulatingagentrefractoryorintolerantpatientswithlowerriskmyelodysplasticsyndromeswithringsideroblasts AT zeidanamerm longtermutilizationandbenefitofluspaterceptintransfusiondependenterythropoiesisstimulatingagentrefractoryorintolerantpatientswithlowerriskmyelodysplasticsyndromeswithringsideroblasts AT garciamaneroguillermo longtermutilizationandbenefitofluspaterceptintransfusiondependenterythropoiesisstimulatingagentrefractoryorintolerantpatientswithlowerriskmyelodysplasticsyndromeswithringsideroblasts AT bucksteinrena longtermutilizationandbenefitofluspaterceptintransfusiondependenterythropoiesisstimulatingagentrefractoryorintolerantpatientswithlowerriskmyelodysplasticsyndromeswithringsideroblasts AT mitevadimana longtermutilizationandbenefitofluspaterceptintransfusiondependenterythropoiesisstimulatingagentrefractoryorintolerantpatientswithlowerriskmyelodysplasticsyndromeswithringsideroblasts AT keepermankaren longtermutilizationandbenefitofluspaterceptintransfusiondependenterythropoiesisstimulatingagentrefractoryorintolerantpatientswithlowerriskmyelodysplasticsyndromeswithringsideroblasts AT holotnatalia longtermutilizationandbenefitofluspaterceptintransfusiondependenterythropoiesisstimulatingagentrefractoryorintolerantpatientswithlowerriskmyelodysplasticsyndromeswithringsideroblasts AT nadaljosealberto longtermutilizationandbenefitofluspaterceptintransfusiondependenterythropoiesisstimulatingagentrefractoryorintolerantpatientswithlowerriskmyelodysplasticsyndromeswithringsideroblasts AT laiyinzhi longtermutilizationandbenefitofluspaterceptintransfusiondependenterythropoiesisstimulatingagentrefractoryorintolerantpatientswithlowerriskmyelodysplasticsyndromeswithringsideroblasts AT vodalasadanand longtermutilizationandbenefitofluspaterceptintransfusiondependenterythropoiesisstimulatingagentrefractoryorintolerantpatientswithlowerriskmyelodysplasticsyndromeswithringsideroblasts AT rosettanibarbara longtermutilizationandbenefitofluspaterceptintransfusiondependenterythropoiesisstimulatingagentrefractoryorintolerantpatientswithlowerriskmyelodysplasticsyndromeswithringsideroblasts AT giuseppianacarolina longtermutilizationandbenefitofluspaterceptintransfusiondependenterythropoiesisstimulatingagentrefractoryorintolerantpatientswithlowerriskmyelodysplasticsyndromeswithringsideroblasts AT yucelaylin longtermutilizationandbenefitofluspaterceptintransfusiondependenterythropoiesisstimulatingagentrefractoryorintolerantpatientswithlowerriskmyelodysplasticsyndromeswithringsideroblasts AT fenauxpierre longtermutilizationandbenefitofluspaterceptintransfusiondependenterythropoiesisstimulatingagentrefractoryorintolerantpatientswithlowerriskmyelodysplasticsyndromeswithringsideroblasts |